Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
NCT03416153Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2018
- Primary completion
- May 2023
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial in oropharyngeal cancer (2 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Local Regional Recurrence at 1 year and Change in Metabolic Tumor Volume 50% at 2 months. Started May 2018; status: completed.
02
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT03416153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03416153.